Institute of Digestive Health and Liver Diseases, Mercy Medical Center, Baltimore, MD, 21202, USA.
Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.
Hepatol Int. 2019 Sep;13(5):534-545. doi: 10.1007/s12072-019-09970-3. Epub 2019 Jul 30.
NAFLD is a spectrum of liver disease starting with fatty liver at one end of the spectrum and cirrhosis or liver cancer at the other end. Worldwide, NAFLD has become one of the most common liver diseases and it has also become one of the leading indications for liver transplantation. Our understanding of the NAFLD epidemiology, pathogenesis and its progression to cirrhosis has improved over the last 2 decades. Currently, however, there are no FDA-approved treatment options for fibrosis resulting from NAFLD. A number of compounds targeting multiple pathways involved in the progression of NAFLD are currently in phase 2-3 trials. In this review, we will briefly discuss the epidemiology, the pathogenesis and the current status of treatment of NAFLD.
非酒精性脂肪性肝病（NAFLD）是一种肝脏疾病谱，从一端的脂肪肝开始，另一端则为肝硬化或肝癌。在全球范围内，NAFLD 已成为最常见的肝脏疾病之一，也是肝移植的主要指征之一。在过去的 20 年中，我们对 NAFLD 的流行病学、发病机制及其向肝硬化的进展有了更多的了解。然而，目前还没有 FDA 批准的治疗非酒精性脂肪性肝病纤维化的方法。目前有许多针对非酒精性脂肪性肝病进展过程中多个途径的化合物正在进行 2-3 期临床试验。在这篇综述中，我们将简要讨论非酒精性脂肪性肝病的流行病学、发病机制和治疗现状。
